Todo T - Search Results

1

Oncolytic virus therapy for prostate cancer.

Fukuhara H, Homma Y, Todo T. Fukuhara H, et al. Among authors: todo t. Int J Urol. 2010 Jan;17(1):20-30. doi: 10.1111/j.1442-2042.2009.02383.x. Epub 2009 Oct 13. Int J Urol. 2010. PMID: 19832925 Review.

2

Oncolytic virus therapy using genetically engineered herpes simplex viruses.

Todo T. Todo T. Hum Cell. 2002 Sep;15(3):151-9. doi: 10.1111/j.1749-0774.2002.tb00109.x. Hum Cell. 2002. PMID: 12703545 Review.

3

[Brain tumor therapy using replication--competent virus vectors].

Todo T. Todo T. Nihon Rinsho. 2005 Sep;63 Suppl 9:504-9. Nihon Rinsho. 2005. PMID: 16201572 Review. Japanese. No abstract available.

4

Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.

Fukuhara H, Martuza RL, Rabkin SD, Ito Y, Todo T. Fukuhara H, et al. Among authors: todo t. Clin Cancer Res. 2005 Nov 1;11(21):7886-90. doi: 10.1158/1078-0432.CCR-05-1090. Clin Cancer Res. 2005. PMID: 16278413

5

Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.

Fukuhara H, Ino Y, Kuroda T, Martuza RL, Todo T. Fukuhara H, et al. Among authors: todo t. Cancer Res. 2005 Dec 1;65(23):10663-8. doi: 10.1158/0008-5472.CAN-05-2534. Cancer Res. 2005. PMID: 16322208

6

Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy.

Ino Y, Saeki Y, Fukuhara H, Todo T. Ino Y, et al. Among authors: todo t. Clin Cancer Res. 2006 Jan 15;12(2):643-52. doi: 10.1158/1078-0432.CCR-05-1494. Clin Cancer Res. 2006. PMID: 16428511

7

[Clinical application of replication-competent herpes simplex virus type 1 vectors for brain tumor therapy].

Miyamoto S, Todo T. Miyamoto S, et al. Among authors: todo t. Nihon Rinsho. 2006 Mar;64 Suppl 3:355-60. Nihon Rinsho. 2006. PMID: 16615498 Review. Japanese. No abstract available.

8

Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.

Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza RL, Rabkin SD, Kurtz A. Liu TC, et al. Among authors: todo t. Mol Ther. 2006 Dec;14(6):789-97. doi: 10.1016/j.ymthe.2006.07.011. Epub 2006 Oct 10. Mol Ther. 2006. PMID: 17045531 Free article.

9

Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.

Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A, Rabkin SD. Liu TC, et al. Among authors: todo t. Clin Cancer Res. 2006 Nov 15;12(22):6791-9. doi: 10.1158/1078-0432.CCR-06-0263. Clin Cancer Res. 2006. PMID: 17121900

10

Oncolytic herpes simplex virus type 1 and host immune responses.

Fukuhara H, Todo T. Fukuhara H, et al. Among authors: todo t. Curr Cancer Drug Targets. 2007 Mar;7(2):149-55. doi: 10.2174/156800907780058907. Curr Cancer Drug Targets. 2007. PMID: 17346106 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

342 results

Search Page

Filters